课题基金 / 基金详情

The effect of Inhaled Nicotine on Pulmonary Surfaces

The effect of Inhaled Nicotine on Pulmonary Surfaces
吸入尼古丁对肺表面的影响
批准号:
10089471
负责人:
Mehmet Kesimer
金额:
$55.72万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-01 至 2022-11-30

项目摘要

项目成果

Mehmet Kesimer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Nicotine is the pharmacologically active/addictive compound in tobacco. As such, the lung serves as an ideal and efficient delivery route for nicotine absorption into the bloodstream where it can then cross the blood brain barrier and induce psychotropic effects on the brain. Recently, with the advent of electronic cigarettes (E- Cigs), people have begun inhaling purified nicotine in a liquid vehicle (typically vegetable glycerin/propylene glycol). While the effects of nicotine on the brain and cardiovascular system are well known, the effects of nicotine on the lung have been less studied. Mucus clearance is a major part of the lung's innate defense system and represents the first point of contact of the body with inhaled nicotine. Perturbations in CFTR- mediated ion transport, which is required for mucus hydration/clearance, or biochemical alterations to mucins impair this system, leaving the lung more prone to mucus accumulation/plugging and viral infections, as evidenced by cystic fibrosis and chronic bronchitis lung disease. Our preliminary data indicate that E-cig users have a drastically altered mucus proteome which is suggestive of immunosuppression. In vitro, we found that nicotine, acting through intracellular Ca2+ (i) dephosphorylated CFTR leading to CFTR inactivation and internalization to the endoplasmic reticulum and (ii) altered mucin rheology by directly interacting with mucins. Furthermore, our data also suggest that the normal ability of the airways to activate CFTR and secrete mucins to generate an “airway flush” to remove inhaled viruses is impaired following nicotine exposure, which is predicted to lead to a failure to resolve common viral infections such as respiratory syncytial virus. We hypothesize therefore, that nicotine causes an immunosuppressed phenotype that leaves the lung more prone to viral exacerbations. Specifically, we propose that (i) nicotine-induced Ca2+ signaling leads to CFTR dephosphorylation and internalization to the endoplasmic reticulum (ii) altered mucus rheology and (iii) a failure to efficiently resolve viral infections. We shall study this hypothesis with the following specific aims: Aim 1. To test the hypothesis that nicotine, via increases in intracellular Ca2+, causes CFTR dephosphorylation and retrograde transport of CFTR to the ER that leads to ASL dehydration. Aim 2. To assess the impact of nicotine on mucin secretion, mucus/mucin biophysical and barrier properties, including their integrity, polymeric structure, and maturation. Aim 3. To determine the impact of inhaled nicotine on outcomes of respiratory virus infection in vivo.
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
Tobacco exposure inhibits SPLUNC1-dependent antimicrobial activity.
烟草暴露会抑制 SPLUNC1 依赖性抗菌活性。
DOI: 10.1186/s12931-019-1066-2
发表时间: 2019
期刊: Respiratory research
影响因子: 5.8
作者: [Moore,PatrickJ, Sesma,Juliana, Alexis,NeilE, Tarran,Robert]
通讯作者: Tarran,Robert
DOI: 10.1371/journal.pone.0254248
发表时间: 2021
期刊: PloS one
影响因子: 3.7
作者: [Bearham J, Krutrök N, Lindberg B, Woodall M, Astrand A, Taylor JD, Biggart M, Vasiljevs S, Tarran R, Baines DL]
通讯作者: Baines DL
DOI: 10.1093/ntr/ntaa177
发表时间: 2020-12-15
期刊: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
影响因子: --
作者: [Correia-Álvarez E, Keating JE, Glish G, Tarran R, Sassano MF]
通讯作者: Sassano MF
Loose ENDs: Electronic Nicotine Delivery Systems and the FDA's Recent Enforcement Policy.
松散的电子烟头:电子尼古丁输送系统和 FDA 的最新执法政策。
DOI: --
发表时间: 2020
期刊: European medical journal. Respiratory
影响因子: --
作者: [Ahmad,Saira, Sassano,MFlori, Tarran,Robert]
通讯作者: Tarran,Robert
7
    Core B: Mucus/Mucin Analytics Core
    The effect of Inhaled Nicotine on Pulmonary Surfaces
    The effect of Inhaled Nicotine on Pulmonary Surfaces
    Core B: Analytics for Mucolytics Core
    海外基金